Segall Bryant & Hamill’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $10.9M | Sell |
1,220,077
-110,237
| -8% | -$988K | 0.15% | 214 |
|
|
2025
Q1 | $9.98M | Sell |
1,330,314
-91,882
| -6% | -$689K | 0.15% | 216 |
|
|
2024
Q4 | $10.7M | Sell |
1,422,196
-68,180
| -5% | -$513K | 0.15% | 213 |
|
|
2024
Q3 | $11.3M | Sell |
1,490,376
-36,105
| -2% | -$274K | 0.15% | 206 |
|
|
2024
Q2 | $9.43M | Sell |
1,526,481
-222,967
| -13% | -$1.38M | 0.17% | 200 |
|
|
2024
Q1 | $8.89M | Buy |
1,749,448
+10,131
| +0.6% | +$51.5K | 0.17% | 211 |
|
|
2023
Q4 | $10.4M | Sell |
1,739,317
-278,669
| -14% | -$1.67M | 0.2% | 180 |
|
|
2023
Q3 | $14.3M | Sell |
2,017,986
-19,702
| -1% | -$139K | 0.17% | 164 |
|
|
2023
Q2 | $14.3M | Buy |
2,037,688
+199,834
| +11% | +$1.41M | 0.15% | 180 |
|
|
2023
Q1 | $15.3M | Buy |
1,837,854
+168,855
| +10% | +$1.41M | 0.17% | 167 |
|
|
2022
Q4 | $19.2M | Sell |
1,668,999
-12,190
| -0.7% | -$140K | 0.21% | 139 |
|
|
2022
Q3 | $21.2M | Sell |
1,681,189
-142,020
| -8% | -$1.79M | 0.25% | 116 |
|
|
2022
Q2 | $19.3M | Buy |
1,823,209
+879,417
| +93% | +$9.31M | 0.22% | 130 |
|
|
2022
Q1 | $15.3M | Buy |
+943,792
| New | +$15.3M | 0.15% | 166 |
|